Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2003

View Archived Issues

Spotlight on S-adenosyl-L-methionine (SAMe)

Kyoto Pharmaceutical presents novel glucose- and lipid-lowering agents

Elan and Pharmacia jointly report new series of beta-secretase inhibitors

Novel SGLT-1 inhibitors prepared and tested at Kissei

Mochida researchers identify analgesic agents resistant to metabolic degradation

Permeation enhancers discovered by Allergan scientists

New atrial-selective antiarrhythmic agents covered by Nissan Chemical patent

Yamanouchi reports novel VEGF inhibitors

Mitsubishi Pharma reports novel PARP inhibitors with utility in cerebral infarction

QRX-101 phase II trial in psoriasis cleared to begin

First clinical trial of ACP-103, targeted for treatment-induced dysfunction in Parkinson's disease

G17DT recommended for orphan drug status in E.U.

Velcade NDA submitted for multiple myeloma

Positive findings for Nastech's intranasal sumatriptan

Theratechnologies acquires new peptide with potential application in diabetes

European launch of Cialis under way

PT-141 effective in ED patients who fail to respond to Viagra

Arestin approved in Sweden

Amgen submits sBLA for Enbrel in ankylosing spondylitis

Geron reports new data on hematopoietic cell production from hESCs

Geron refocuses resources

New treatment option for COPD nearing approval in Europe

Divalproex sodium reported safer than olanzapine in bipolar disorder

Two courses of alefacept evaluated in patients with chronic plaque psoriasis

Antiinflammatory effects of omega-3 fatty acids

Teijin and Kyorin to form new company

Reduced parenteral nutrition requirement with rhGH and glutamine in short bowel syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...